


PHARMACEUTICAL 2017

Regulus Therapeutics Inc. Rank 215 of 313







PHARMACEUTICAL 2017

Regulus Therapeutics Inc. Rank 215 of 313



The relative strengths and weaknesses of Regulus Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Regulus Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 64% points. The greatest weakness of Regulus Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 190% points.

The company's Economic Capital Ratio, given in the ranking table, is -373%, being 44% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	87,474
Cost of Goods Sold	0
Intangible Assets	1,015
Liabilities, Current	13,807
Liabilities, Non-Current	144
Other Assets	342
Other Compr. Net Income	10
Other Expenses	1,178
Other Liabilities	30,635
Other Net Income	0
Property and Equipment	11,830
Research and Development	64,305
Revenues	2,038
Selling, General and Administrative Expense	18,391

Output Variable	Value in 1000 USD
Assets	100,661
Liabilities	44,586
Expenses	83,874
Stockholders Equity	56,075
Net Income	-81,836
Comprehensive Net Income	-81,831
Economic Capital Ratio	-373%